Blog Profile / Health Care Renewal

Filed Under:Industries / Medical
Posts on Regator:1004
Posts / Week:2.8
Archived Since:November 10, 2008

Blog Post Archive

Academic Medical Leaders as Directors of For-Profit Health Care Corporations: the Prevalence of This "New Species" of Conflict of Interest Documented in the BMJ

The important conflicts of interest generated when academic health care leaders also serve on the boards of directors of for-profit health care corporations is suddenly less anechoic, thanks to some intrepid researchers and the British Journal of Medicine. Show More Summary

Cambridge University Hospitals Trust IT Failures: An Open Letter to Queen Elizabeth II on Repeated EHR Failures in the United Kingdom, Even After £12.7bn Wasted in Failed NHS National IT Programme

Dear Queen Elizabeth,I am an American citizen who has written for years about healthcare information technology mismanagement (IT malpractice), dangers to patients of this technology when faulty in healthcare, and the huge mania or bubble...Show More Summary

Turn That Door Around - A Physician Substantially Tied to the Pharmaceutical Industry Nominated to Run the FDA

It seems to be the season of the revolving door in health care. The latest version got some media attention, because it involves one of the most important health care leadership positions in the US government, the Director of the Food and Drug Administration (FDA). Show More Summary

A Quiet Turn of the Revolving Door - Director of NIMH to Go Directly to Google Life Sciences

Amidst a lot of health care news, the job plans of Dr Thomas Insel, currently the director of the National Institute of Mental Health (part of the US National Institute of Health) made a very small splash. The most comprehensive account was in the New York Times.Dr. Show More Summary

Politico 2015: EHR sellers using “gag clauses” (despite Koppel's 2009 JAMA article on EHR nondisclosure clauses, and my 2009 JAMA Letter to the Editor on how these clauses violate Joint Commission safety standards)

I have not blogged on EHR issues in some time, despite some interesting source material such as "Evidence Summary: Electronic Health Records (EHRs)" at ; "Electronic Health Records...Show More Summary

Pfizer's Latest International Pfiascos - Charges of Anti-Competitive Practices, Inflated Prices, Deception and Secrecy

Many big health care organizations seem to just be unable to keep out of trouble, and the bigger they are, the more kinds of trouble. Pfizer Inc, considered to be one of the world's largest pharmaceutical companies, has supplied us with plenty of stories. Show More Summary

Round and Round It Goes - Former US Secretary of Health and Human Services Joins Humacyte Board

The latest example of the health care revolving door was made barely public just before the US Labor Day holiday. Per the Triangle Business Journal,Humacyte Inc., a biotechnology company based in Research Triangle Park, has beefed up its board of directors by adding former U.S. Show More Summary

Northwestern Upholds its "Brand," Never Mind Free Speech and Academic Freedom

Threats to free speech and academic freedom in health care were a major concern when we started Health Care Renewal. Such threats may now be less anechoic, but do not seem to have diminished.Censorship and the Resignation of Alice Dreger The latest example was at Northwestern University. Show More Summary

You Can Check Out Any Time You Like, But You Can Never Leave - Duke and UNC Allegedly Agreed Not to Hire Each Other's Faculty

We have intermittently discussed the worsening plight of physicians trying to provide clinical care as employees of large organizations. Such corporate physicians are likely to be squeezed between professional values that put the patient first, and management that puts revenue first. Show More Summary

The Real Dark Side of Health Care: Health Care Corruption

The editors of the prestigious Annals of Internal Medicine just stated they they were shocked, shocked to find out that physicians occasionally express disrespect for patients when the patients cannot hear or see them. The occasion was...Show More Summary

Once More with Feeling - Amgen Again Settles Allegations of Misbranding, But Why Bother?

The Latest Settlement Biotechnology giant Amgen has just reached another settlement of allegations that it unfairly, deceptively or misleadingly marketed its drug. Per the Los Angeles Times,Amgen Inc. has agreed to pay $71 million to...Show More Summary

With 10 Health Care Executives on it Board, US Chamber of Commerce Defends Big Tobacco Abroad

Tobacco, especially smoked in cigarettes, is generally recognized by health care professionals as having health hazards that greatly outweigh its benefits to society. Therefore, most health care organizations discourage tobacco use, and many have developed tobacco free policies.However, the tobacco industry has its powerful supporters. Show More Summary

The Latest Example of the Anechoic Effect - AllTrials US Initiative Launches to Deafening Media Silence

Every now and then, someone tries to persuade me how much more open discussion of various kinds of recent unpleasantness in health care has become in the US. I admit there has been more media attention to certain issues, but unfortunately...Show More Summary

Praluent, the Next Expensive "Game Changer," Blockbuster," "New Hope," - But Not Yet Shown to Benefit Patients

Here we go again. The same month that it approved Entresto (look here), the US Food and Drug Administration approved a new PCSK9 inhibitor cholesterol lowering agent, alirocumab, immediately marketed as the pricy Praluent by Sanofi and Regeneron, and heralded by a blast of media hype. Show More Summary

60% of the CEOs of America's "Great Health Systems" Have No Educational Background in Health Care

We have noted that US health care has been taken over by generic managers. A recent article about the CEOs of purportedly some of America's best hospitals provides some quantitative data.A few days ago, Becker's Hospital Review published...Show More Summary

Entresto, Blockbuster, or Just Over Hyped? - Whatever, It Will Cost $4500 a Year

The newest drug for congestive heart failure, Entresto, a fixed combination of valsartan and sacubitril, has just hit the market at an elevated price. Like other drugs recently introduced as blockbusters, the high price does not seem clearly justified by clinical evidence about the drug's benefits and harms. Show More Summary

What They Really Think of Us, UK Version - Health Secretary Derides NHS Doctors for Not Working Enough on Weekends

A new story from the UK suggests what top leaders of health care really think about health care professionals. I realize that I risk showing my shallow understanding of UK politics when I comment on this, but I believe that the story...Show More Summary

Turn, Turn, Turn - from Colubia/ HCA Executive, to Virginia Secretary of Health and Human Resources, to Director of the Center for Medicare and Medicaid Services (CMS), to America's Healt Insurance Plans (AHIP)

Marilyn Tavenner's career continues to revolve, er, evolve.Columbia/ HCAMarilyn Tavenner worked for Columbia / HCA, now HCA, although details of her job there are sketchy. Apparently she worked there for a long time, according to a 2015...Show More Summary

Who Benefits? - Rising Generic Drug Prices and the Case of Mylan's Conflicted Property Purchases

Rising Generic Drug PricesHealth care costs in the US continue their seemingly inexorable rise. Even the parts of health care that used to seem reasonably priced now are affected. As Ed Silverman discussed on PharmaLotprices for many generic drugs have been climbing, prompting concerns that a low-cost staple of the U.S. Show More Summary

Bill Clinton, Paid to Speak to Biotech Conference, Extolled $1000 Pill to Prevent "Liver Rot," Despite Lack of Evidence that It Does

What were they thinking?Former President Clinton Talkes to Pharma and Biotech Executives In mid June, 2015, the Philadelphia Inquirer reported that former US PresidentClinton was the keynote speaker at Klick Ideas Exchange, sponsored...Show More Summary

Copyright © 2015 Regator, LLC